ACHE and Alzheimer disease: Optically pure (−)-galanthamine, another traditional AChE inhibitor that has received clinical approval for the treatment of mild to moderate dementia in patients with AD [110], is also used in the development of potential radiopharmaceutical probes for imaging brain AChE.